PTC Therapeutics acquiert ST-920 pour la maladie de Fabry ; soumission de la BLA prévue au T4 2026

PTC Therapeutics a acquis le programme de thérapie génique AAV ST-920 pour la maladie de Fabry auprès de Sangamo pour 111 M$ initiaux plus jusqu'à 100 M$ en jalons réglementaires. La société s'attend désormais à finaliser la soumission de la BLA au T4 2026, avec une approbation accélérée potentielle et un lancement commercial en 2027.

Faits clés

Déposé: 29 oct. 2026, 20:10
Événement: Dossier soumis
Direction: Neutre
Société: PTCTPTC Therapeutics
Actif: isaralgagene civaparvovec
Source: SEC 8-K
Fiabilité: Sourcé
paiement initial: 111 millions de dollars
jalons conditionnels: jusqu'à 100 millions de dollars

Extrait de la source

EX-99.1 2 tmb-ex99d1.htm EX-99.1 Exhibit 99.1 PTC Therapeutics Provides Corporate Update and Reports Third Quarter 2026 Financial Results – Strong Q3 2026 performance with total revenue of $358 million, including $276 million of product revenue – – Full-year 2026 expected total revenue increased to $1.29 to $1.32 billion, with full-year product revenue guidance raised to $960 to $990 million – – Sephience™ (sepiapterin) Q3 2026 revenue of $182 million, with continued growth in the US and ongoing global expansion – – Acquired ST-920 Fabry disease gene therapy; BLA submission expected to be completed in Q4 2026 – WARREN, N.J., October 29, 2026 – PTC Therapeutics, Inc., (NASDAQ: PTCT) today announced a corporate update and financial results for the third quarter ended September

SEC 8-K